Q2 FY2026 EarningsQ2 FY2026 outperformed consensus estimates significantly, driven by an 18.2% beat in revenue ($23.4M vs. $19.7M expected) and a robust gross margin of 91.4% vs. 85.1% consensus. The Interventional Dry Eye segment saw a 703% YoY revenue surge following favorable Medicare reimbursement updates. Diluted GAAP EPS of -$0.08 beat the -$0.14 estimate by $0.06, supported by lower-than-expected R&D spending and one-time tariff recoveries.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Sight Sciences(SGHT) the Revenue is 23.39 M (+19.55%), Beat estimate;the EBIT is -3.888 M (+66.68%), Beat estimate;the EPS is -0.08 (+65.22%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.02B19.55%
0.02B10.88%
+0.00B8.67%
EBITExceed expectations
-0.00B66.68%
-0.01B37.68%
+0.00B29.00%
EPSExceed expectations
-0.0865.22%
-0.14238.27%
+0.062026.95%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf